Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05227339 · ClinicalTrials.gov registry record · Phase 2

RAE (Realize, Analyze, Engage)

A Phase 2 study of Substance Use Disorders and Treatment Adherence and Compliance, sponsored by ContinueYou.

Completed
Registry status
Phase 2
Development phase
209
Enrollment target
1
Study location

NCT05227339 is a Phase 2 study of Substance Use Disorders and Treatment Adherence and Compliance that has completed, run by ContinueYou. The registered enrollment target is 209 participants, below the 498-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05227339, a Phase 2 study of Substance Use Disorders and Treatment Adherence and Compliance, has completed, sponsored by ContinueYou.

COMPLETED
Registry status
Phase 2
Development phase
209 participants
Enrollment target
1
Study location

Study Summary

The proposed study will evaluate the detection of digital biomarkers of stress, and drug craving in a population of individuals undergoing treatment for substance use disorder

Interventions

  • DEVICE RAE

Study Locations (1)

Massachusetts

  • University of Massachusetts Chan Medical School - Worcester

Trial Details

FieldValue
Enrollment Target 209 participants
Start Date 2022-02-22
Est. Completion 2024-04-01
Phase Phase 2

Sponsor

ContinueYou

1 total trials

What the Registry Record Tells You About NCT05227339

The ClinicalTrials.gov registry entry for NCT05227339 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 498-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (58% lower). The listed sponsor is ContinueYou, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 1 intervention - of which RAE is the first listed.

NCT05227339 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05227339 about?

NCT05227339 is a clinical study titled "RAE (Realize, Analyze, Engage)". The proposed study will evaluate the detection of digital biomarkers of stress, and drug craving in a population of individuals undergoing treatment for substance use disorder

What is the current status of trial NCT05227339?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2022-02-22. Estimated completion is 2024-04-01.

What conditions does trial NCT05227339 study?

This clinical trial studies the following conditions: Substance Use Disorders, Treatment Adherence and Compliance.

What interventions are being tested in trial NCT05227339?

The interventions under investigation include: RAE (DEVICE).

Who is sponsoring clinical trial NCT05227339?

This trial is sponsored by ContinueYou, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05227339 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Use Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.